Estimation of (suPAR) in Chronic Periodontitis With Post-radiotherapy on HNCs Patients

Al-Maarif University College

Status: Completed

Conditions: Radiotherapy Side Effect; Chronic Periodontitis; Head and Neck Cancer

Treatments: Radiation: Radiation

Study type: Observational

Funder types: Other

Identifiers

NCT06529588

suPAR as a potential biomarker

Details and patient eligibility

About

This study aims to improve a soluble urokinase plasminogen activator receptor suPAR is a reliable biomarker of chronic periodontitis and may be replaced in patients with head and neck cancer post-radiotherapy (HNC post-RT).

Full description

The urokinase-type plasminogen activator receptor (uPAR) plays an essential function in leukocytes and endothelial homeostasis and, therefore, in the development of chronic periodontitis. The study enrolled 150 participants, 50 chronic periodontitis with head and neck cancer post radiotherapy (CP+HNC post-RT) patients, 50 chronic periodontitis (CP) without HNC patients, and 50 healthy controls. Clinical Attachment Loss (CAL), Probing Pocket Depth (PPD), Plaque Index (PI), and Gingival Bleeding Index (GBI) were recorded. An enzyme-linked immunosorbent assay (ELISA) was constructed to quantify serum (suPAR) levels.

Enrollment: 150 patients

Sex: All

Ages: 28 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• A pathologically confirmed malignant neoplasm of HNC (derived from epithelial cells).
• Not having received radiation therapy previously.
• No distant metastasis.
• No history of salivary gland surgery (parotid, submandibular, or sublingual).
• A generally satisfactory physical condition with a performance score of 0 to 1 point and a planned survival period of more than a year and scores of 2 higher indicating increasing disability.

Exclusion criteria

• Previous oral disease or salivary gland disease history.
• Definitive diagnosis of multiple sclerosis, xerostomia, or systemic disease.
• Refusal to participate in the study.

Trial design

150 participants in 1 patient group

Head and neck cancer post-radiotherapy

Description:

Head and Neck cancer patients who received radiotherapy (32-35 fractions) exposure (5700-7000 Gys) addition chemotherapy (cisplatin or cetuximab (2-3 dosages).

Treatment:

Radiation: Radiation